Special Issue

Glycosylation Pathway Genes in Health and Disease: From Models to Pathobiology of Genetic Defects

Message from the Guest Editor

Glycosylation is the most common posttranslational protein modification and participates in a multitude of molecular and cellular interactions, affecting normal physiological processes as well as disease conditions. Congenital defects in glycosylation pathways lead to severe disorders, including muscular dystrophy, neurological abnormalities, developmental defects, and other severe pathologies.

The present Special Issue, entitled “Glycosylation pathway genes in health and disease: From models to pathobiology of genetic defects”, is intended to function as a forum for the discussion of the most recent advances in interdisciplinary research on the function of glycosylation genes, genetic mechanisms of glycosylation in the nervous system, and the pathobiology of glycosylation defects revealed by in vitro and in vivo models, as well as clinical studies. The issue is expected to include reviews, original studies reporting new results and method papers describing novel approaches. For further information about the scope of the issue and preferred manuscript topics, please contact the .

Guest Editor

Dr. Vladislav Panin
Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA

Deadline for manuscript submissions

closed (15 October 2021)

GCAT
TACG
GCAT

Genes

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed

mdpi.com/si/71998

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

mdpi.com/journal/genes

MDPI

GCAT
TACG
GCAT

Genes

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed

mdpi.com/journal/genes

MDPI

About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))